onepharm is a Vienna, Austria based innovative dental-pharmaceutical company.
June 26, 2006
onepharm has obtained funding of over 3.5 million euros

Vienna – June 25, 2006 – onepharm, a Viennese biotech company specializing in the development of new antiviral drugs, has been awarded funding of over 3.5 million euros. “With this funding and our outstanding team, which now numbers 10 staff and experts, our projects in the development of new drugs to combat viral respiratory tract diseases are now right on track” enthused Dr. Bernhard Küenburg, CEO of onepharm.

The funding is made up of various components: Firstly, in addition to dormant equity holdings, an additional Austrian private investor has been persuaded to make a substantial investment in the form of an increase in share capital. Secondly, onepharm has received funding from Austria Wirtschaftsservice (AWS) under their “Seed Financing” and “High-Tech Double Equity” programs, and from the Research Promotion Agency (FFG).

The establishment up of a “Vienna Spot of Excellence” (VSOE) has been agreed with the ZIT (Zentrum für Innovation und Technologie, the City of Vienna Center for Innovation and Technology). In this project, supported by ZIT to the tune of more than 1.3 million euros under the name ASPEX Vienna (Antiviral Spot of Excellence - Vienna), it is planned to set up a three-year collaboration program with the University of Natural Resources and the Vienna University of Technology. Its aim is the chemical modification of OPM-3001, one of onepharm’s two lead products, in order to identify, by means of such modification, products with heightened antiviral activity. The deputy mayor of Vienna, Dr. Sepp Rieder, announced the funding at a recent press conference and stressed the importance of pharmaceutical research for the Vienna area.
 

“It gives us great pleasure that, with the ASPEX project, we have been able to convince a top international jury of the quality of our project plan and to have obtained such substantial funding” said Küenburg. “The overall financial package of both private and public funding demonstrates once again the attractiveness of Vienna as a location for new biotech enterprises. This is a place where the research and development of new pharmaceutical products will receive consistent and continued support.”


About onepharm
onepharm was co-founded by its management and Green Hills Biotechnology in 2005. The company specializes in the development of new drugs in the field of viral respiratory tract diseases such as the common cold, influenza, bird flu, and SARS. With OPM-1001 and OPM-3001 onepharm already has a product portfolio with which preclinical and clinical trials can be started in the very near future. Both projects also provide the basis for extensive scientific work to identify new active substances and clinical applications.

Contact:
onepharm Research & Development GmbH
Dr. Bernhard Küenburg, CEO
Gersthoferstr. 29-31
A-1180 Vienna, Austria
Tel: +43 1 890 2992
Fax: +43 1 890 2992 15
bernhard.kueenburg(at)onepharm.com
www.onepharm.com